Re: Fluff PR
I was actually looking at Cardio3 this weekend to see if there was a way to time / trade the stock on the downside.
Their PR is fantastically fluffy. They put out a press release every time their ongoing phase 3 trial in Europe opened a center in one of the EU countries. Suffice to say that's a lot of PRs announcing trial site openings.
Almost better, they put out a PR noting that their work was mentioned in a review published in Nature Reviews Cardiology. At least one of the authors of that review worked at Cardio3 for some type, 2 of the authors have, at least in the past, had financial interests associated with the company, and another of the authors is now on the board of directors.
Fluff... and maybe even unethical fluff.
---
For those interested, Cardio3 has a futility analysis for one of their phase 3 trials scheduled for March, 2015. I'm fairly certain this trial is a giant bust, but uncertain if there is enough leeway in the futility analysis to allow the company to simply proceed with a failing trial.
